


Active Filter(s):
Details:
Halozyme and Antares will create a drug delivery and specialty product company. The Antares business consists of a best-in-class, auto injector and ENHANZE platform that offers broad licensing opportunity, with 3 commercial products including Tlando (testosterone undecanoate).
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Halozyme Therapeutics
Deal Size: $960.0 million Upfront Cash: $960.0 million
Deal Type: Acquisition May 24, 2022
Details:
TLANDO® is an oral treatment for testosterone replacement therapy indicated for conditions associated with a deficiency or absence of endogenous testosterone in adult males.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: Approved Product Type: Small molecule
Recipient: Lipocine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
The combination of Halozyme and Antares will create a drug delivery and specialty product company. The Antares business consists of a best-in-class, auto injector and ENHANZE platform that offers broad licensing opportunity, with 3 commercial products including Tlando.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Halozyme Therapeutics
Deal Size: $960.0 million Upfront Cash: $960.0 million
Deal Type: Acquisition April 13, 2022
Details:
TLANDO ® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”) indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Lipocine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
The results of the Phase I study met its primary objective showing ATRS-1902 delivered a comparable pharmacokinetic profile and also demonstrated that ATRS-1902 was safe and well-tolerated for the treatment of acute adrenal insufficiency.
Lead Product(s): Hydrocortisone
Therapeutic Area: Endocrinology Product Name: ATRS-1902
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2022
Details:
Under the terms of the definitive agreements, Assertio acquired Otrexup from Antares in a partially seller financed transaction inclusive of working capital investments. Otrexup is a once weekly single dose auto-injector containing a prescription medicine, methotrexate.
Lead Product(s): Methotrexate
Therapeutic Area: Immunology Product Name: Otrexup
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Assertio Holdings
Deal Size: $44.0 million Upfront Cash: $18.0 million
Deal Type: Acquisition December 15, 2021
Details:
In granting tentative approval, the FDA concluded that TLANDO® met all required efficacy, quality and safety standards necessary for approval and will be eligible for final approval and marketing in the U.S.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: Approved Product Type: Small molecule
Recipient: Lipocine
Deal Size: $25.0 million Upfront Cash: $11.0 million
Deal Type: Licensing Agreement October 18, 2021
Details:
The active IND enables Antares to initiate a Phase 1 clinical study for ATRS-1902 for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.
Lead Product(s): Hydrocortisone
Therapeutic Area: Endocrinology Product Name: ATRS-1902
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
This license agreement for NOCDURNA expands Antares Pharma's urology portfolio, which already includes XYOSTED, the best-selling branded testosterone replacement product in the United States.
Lead Product(s): Desmopressin Acetate
Therapeutic Area: Urology Product Name: Nocdurna
Highest Development Status: Approved Product Type: Large molecule
Recipient: Ferring Pharmaceuticals
Deal Size: $25.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement October 01, 2020
Details:
Antares development partner Teva, launched Teriparatide Injection (“teriparatide”), the generic version of Eli Lilly’s brand product Forsteo® featuring the Antares multi-dose pen platform in Austria, Croatia, Hungary,
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020